Aardvark Books Q1 2027 FDA Meeting to Map ARD-101 Restart After Hold Lifted
AARD sits 63% above its 52-week low of $0.93 on light trading volume (0.4× avg).
Summary
Aardvark's Q3 release confirms the $19.2M quarterly loss and $60.3M cash balance already reported, and adds the key new item: an FDA meeting in Q1 2027 to agree on the ARD-101 PWS development plan, with clinical work expected to restart in 2027.
Key Events · Earnings and Guidance · AARD
-
Q1 2027 FDA Meeting Scheduled
Aardvark has requested and been scheduled a meeting with the FDA for the first quarter of 2027 to discuss its proposed ARD-101 clinical development plan in PWS. The company expects to resume PWS clinical activities in 2027, subject to alignment with the agency.
-
Q3 Loss and Cash Balance
Net loss was $19.2M ($0.88 per share) for Q3 2026 versus $16.3M a year earlier. Cash, cash equivalents and short-term investments totaled $60.3M at September 30, 2026, down from $73.9M at June 30, 2026.
-
Runway Through 2027, Phase 3 Funding Gap
Management says existing cash funds projected operations through 2027, but the release separately flags the risk of the ability to raise sufficient capital to fund a planned Phase 3 program — with a $150M at-the-market facility established in March 2026 available as a dilution lever.
-
R&D Spend Rises on Cardiac Safety Work
R&D expense was $15.7M in Q3 2026 versus $13.7M in Q3 2025, a $1.9M increase driven by the FDA-required cardiac safety study of ARD-101 and higher personnel costs, partly offset by lower trial costs after the HERO and OLE terminations.
Analysis · AARD · Life Sciences
The Q3 numbers were already out via the same-day 10-Q and press coverage: a $19.2M net loss and $60.3M in cash. What is new is the calendar. Management now has a first-quarter 2027 FDA meeting booked to argue for its proposed ARD-101 development plan in Prader-Willi syndrome, and it expects clinical activity to resume in 2027 only if the agency agrees. That converts an open-ended post-hold situation into a dated decision point. It also frames the cash question: $60.3M is enough to run the current cost base through 2027, but the press release itself flags the risk that a full Phase 3 program may require more capital — against an existing $150M at-the-market facility established in March 2026. Until the FDA feedback lands, the stock trades on a binary regulatory readout roughly a quarter away.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AARD was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.3M. The 52-week trading range was $0.93 to $16.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.